Results 31 to 40 of about 1,268 (176)

Sequential administration of efgartigimod shortened the course of Guillain–Barré syndrome: a case series [PDF]

Therapeutic Advances in Neurological Disorders
Guillain–Barré syndrome (GBS) is a serious neurological condition with limited treatment options. A recent report demonstrated successful treatment with efgartigimod alone in two patients with GBS, although it did not significantly shorten the disease ...
Sihui Chen, Ruwei Ou, Qianqian Wei, Bi Zhao, Xueping Chen   +4 more
doaj   +2 more sources

Efgartigimod for Guillain–Barré syndrome: a retrospective analysis of efficacy and safety [PDF]

Therapeutic Advances in Neurological Disorders
Background: Guillain–Barré syndrome (GBS) is an acute autoimmune neuropathy with limited effective treatments. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, may offer a novel treatment by reducing pathogenic immunoglobulin G.
Zhuajin Bi, Xiaodong Ye, Peidong Liu, Mengcao Lu, Hongbo Liu, Min Chen   +5 more
doaj   +2 more sources

Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neuro intensive care unit [PDF]

BMC Neurology
Background Myasthenic crisis (MC) refers to rapid deterioration of myasthenia gravis (MG), affecting lung and bulbar muscles and causing breathing difficulties.
Fangyi Shi, Rong Lai, Li Feng, Hongyan Zhou, Xunsha Sun, Cunzhou Shen, Jiezhen Feng, Zhilong Xu, Haiyan Wang, Huiyu Feng   +9 more
doaj   +2 more sources

The utilization of efgartigimod in the treatment of acute cerebellar ataxia: a case report [PDF]

Frontiers in Immunology
BackgroundAcute cerebellar ataxia (ACA) is the most common cause of acute ataxia in children and adolescents. It is a cerebellar disorder with multifactorial pathogenesis, often triggered by viral or bacterial infections, as well as autoimmune mechanisms.
Liu L. Yang, Yushuang Ruan, Fucheng Cai, Yuanpeng Xia   +3 more
doaj   +3 more sources

Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod

Frontiers in Immunology
ObjectiveWe aimed to explore the efficacy and safety of efgartigimod in patients with refractory immune-mediated necrotizing myopathy (IMNM).MethodsThis open-label pilot observational study included seven patients with refractory IMNM, all of whom received intravenous efgartigimod treatment.
Mengting Yang, Yikang Wang, Hongjun Hao   +2 more
exaly   +4 more sources

Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis [PDF]

Frontiers in Immunology
Anti-GQ1b antibody syndrome is a spectrum of autoimmune neurological disorders that includes Miller Fisher syndrome, Guillain-Barré syndrome (GBS) with ophthalmoplegia, Bickerstaff brainstem encephalitis, and acute ophthalmoplegia without ataxia.
Keiko Watanabe, Seiya Takahashi, Akane Kanda, Takuya Watanabe, Yuki Kakinuma, Satoshi Yano, Ryuta Kinno, Ryuta Kinno   +7 more
doaj   +3 more sources

Efgartigimod-associated Kaposi’s varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review

Frontiers in Immunology
BackgroundEfgartigimod (Efgartigimod alpha fcab, Vyvgart™) is a pioneering neonatal Fc receptor (FcRn) antagonist for the treatment of severe autoimmune diseases mediated by pathogenic immunoglobulin G (IgG) autoantibodies, including myasthenia gravis ...
Lingzhi Ge, Yanyan Li, Ying Sun, Wenfang Chen, Xiaoli Ni, Xiaoli Ni, Fangli Wei, Zhen Mu   +7 more
exaly   +3 more sources

Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study [PDF]

Neurotherapeutics
Early intervention in impending myasthenic crisis (IMC) is critical to avert life-threatening progression. This study compared the clinical effectiveness and safety of the novel FcRn antagonist efgartigimod versus intravenous immunoglobulin (IVIg) in IMC
Rongjing Guo, Chao Sun, Xiaoxi Huang, Sijia Hao, Qingqing Wang, Zhe Ruan, Ting Gao, Yonglan Tang, Xiangqi Cao, Yu Liu, Zhuyi Li, Ting Chang   +11 more
doaj   +2 more sources

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study. [PDF]

Muscle Nerve
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Lin J, Qi G, Luo S, Jiang Q, Bu B, Liu M, Wei Y, Han M, Yang J, Zhao Z, Zhang L, Zhang Y, Xu H, Hao X, Li Z.   +14 more
europepmc   +2 more sources

Efgartigimod Alfa in Generalized Myasthenia Gravis: A Profile of Its Use [PDF]

, 2023
Declarations  Funding The preparation of this review was not supported by any external funding.  Authorship and Conflict of interest Young-A Heo is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Young-A Heo (6594442)
core   +1 more source